retatrutide cagrilintide vs CagriSema: The Battle Nobody's Covering cagrilintide vs tirzepatide vs retatrutide

For anyone exploring the difference between microdosing tirzepatide and standard dosing, the SURMOUNT data makes it clear that sub-therapeutic doses below 5 mg produce minimal weight loss

But as of May 23, 2025, no new compounded semaglutide is legally permitted to be produced or sold

Impact on perioperative glycaemia Less hypoglycaemia risk than insulin and better perioperative glucose control

Observational analyses and randomized clinical trials consistently report nausea, vomiting, diarrhea, constipation, and abdominal discomfort as the most common symptoms, although the distribution of events varies

Moreover, Resmetirom, a thyroid hormone beta receptor agonist, has recently been approved for MASLD treatment

However, this effect is significantly diminished or absent in diabetes